AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29091217
Drug: Cobicistat-boosted elvitegravir
RxNorm normalized name: cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobicistat-boosted elvitegravir (150/150 mg)
Trial: 26863333
Drug: Prostaglandin vaginal
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin vaginal inserts (dinoprostone 10 mg, misoprostol 50 mcg or 100 mcg)
Trial: 18419630
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg oral suspension once daily
Trial: 18419630
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension once daily
Trial: 16864931
Drug: ARB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB plus spironolactone (SPRL) 25 mg/day for 6 months
Trial: 16864931
Drug: ARB (candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (candesartan 8 mg/day) for 1 year
Trial: 22854050
Drug: Activated HER-receptors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated HER-receptors (pHER1, pHER2, pHER3)
Trial: 20669668
Drug: Ningxintong Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningxintong Granule (NXTG) combined with Western medical conventional treatment
Trial: 20669668
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical conventional treatment alone
Trial: 10984081
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg single dose)
Trial: 1281046
Drug: EDX-L (epirubicin-lipiodol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDX-L (epirubicin-lipiodol emulsion)
Trial: 1281046
Drug: EDX-L followed
RxNorm normalized name: EDX-502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDX-L followed by GS (gelatin sponge)
Trial: 1281046
Drug: DX-L (doxorubicin-lipiodol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX-L (doxorubicin-lipiodol emulsion)
Trial: 3969014
Drug: Calcitonin alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin alternating with growth hormone (combined treatment)
Trial: 30040016
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of textured balance board training (1 minute daily)
Trial: 30040016
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of textured balance board training (1 minute daily)
Trial: 29489681
Drug: PO-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO-based administration set
Trial: 29489681
Drug: PU-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PU-based administration set
Trial: 29489681
Drug: PVC-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVC-based administration set
Trial: 27103982
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) at a target dose of 60 mg/kg/day in three divided doses
Trial: 23342619
Drug: Cytoflavin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (in infusion, then oral administration)
Trial: 23342619
Drug: Baseline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline therapy (alpha1‐adrenoblockers, non‐specific anti‐inflammatory drugs, digital prostate massage and vacuum phallostimulation)
Trial: 17703122
Drug: In-home psychotherapy
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home psychotherapy for depressive symptoms; details on dosage and duration not specified.
Trial: 7715941
Drug: Outpatient cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient cognitive-behavioural therapy (CBT) with amitriptyline (AMI)
Trial: 7715941
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy with amitriptyline (AMI)
Trial: 2611615
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFN with vinblastine (0.1 mg/kg every third week)
Trial: 28347975
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders for a 30‐day intervention phase following hospitalization.
Trial: 24138537
Drug: LPV/r 600/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 600/150 mg
Trial: 19496959
Drug: Venlafaxine 150-225
RxNorm normalized name: venlafaxine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 150-225 mg
Trial: 11269898
Drug: Control (drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (drugs only)
Trial: 3969035
Drug: Smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking intervention programme administered by general practitioners
Trial: 25933728
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion strategy (Hb < 11.3 g/dL, 7 mmol/L)
Trial: 25933728
Drug: Restrictive RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive RBC transfusion strategy (Hb < 9.7 g/dL, 6 mmol/L)
Trial: 23903529
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum protein concentrate (CPC) supplementation (10 g/day)
Trial: 23903529
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 g whey protein concentrate/day)
Trial: 22077684
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and dental education in one session for children and parents
Trial: 19936370
Drug: OptiNose's novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiNose's novel delivery device (Opt‐FP) 400 microg twice daily for 12 weeks
Trial: 13680266
Drug: recombinant follicle‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle‐stimulating hormone (rFSH) + human menopausal gonadotrophin (HMG)
Trial: 13680266
Drug: recombinant follicle‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant follicle‐stimulating hormone (rFSH) alone
Trial: 13680266
Drug: short protocol
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short protocol with luteinizing hormone (LH) added from the beginning
Trial: 13680266
Drug: high day
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high day 3 serum FSH concentrations (>9 mIU/ml)
Trial: 11273950
Drug: Ketoprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (100 mg IV during surgery and 8 hours later)
Trial: 9228494
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) patch therapy
Trial: 8427034
Drug: Influenza subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza subunit vaccine (0, 10, 20, and 60 micrograms)
Trial: 3036023
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid (2%) applied twice daily under occlusion
Trial: 3036023
Drug: Novobiocin (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novobiocin (2% or 5%) applied twice daily under occlusion
Trial: 27240787
Drug: Raltegravir group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir group (oral ritonavir-boosted lopinavir 100 mg ritonavir, 400 mg lopinavir plus 400 mg raltegravir twice a day)
Trial: 18266660
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA)‐naive paroxysmal AF
Trial: 12832367
Drug: Oxytocin antagonist
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin antagonist (atosiban)
Trial: 8447842
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 2 mg folic acid
Trial: 8447842
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 2 mg folic acid
Trial: 2447860
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous crystalloid solution and routine ward observations
Trial: 2447860
Drug: Peritoneal lavage
RxNorm normalized name: Peritoneal Lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal lavage as adjunctive therapy
Trial: 24002913
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antiplatelet agents)
Trial: 15881644
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy (CT) plus a composition of replaceable amino acids (CRAA) sublingually and orally
Trial: 15881644
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy (CT) plus melatonin in doses of 3 and 6 mg
Trial: 15881644
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy (CT) only
Trial: 15881644
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy (CT) plus placebo
Trial: 12882479
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity (150 min weekly of moderate intensity physical activity, such as brisk walking)
Trial: 9779029
Drug: Enoxaparin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (lower dose 1.0 mg/kg)
Trial: 8681499
Drug: Tolrestat 200
RxNorm normalized name: tolrestat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolrestat 200 mg orally once daily for six months
Trial: 2796443
Drug: mecillinam (1.200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mecillinam (1.200 mg/day p.o.) for 5 days
Trial: 2796443
Drug: co‐trimoxazole (1.600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co‐trimoxazole (1.600 mg/day p.o.) for 5 days
Trial: 682818
Drug: Subcutaneous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lateral sphincterotomy
Trial: 27130038
Drug: Facial botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial botulinum Toxin‐A (BTX) injections
Trial: 25002389
Drug: Cold static
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold static storage with histidine-tryptophan-ketoglutarate solution (Custodiol)
Trial: 20568303
Drug: peginterferon (PEG‐IFN)
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon (PEG‐IFN) alfa‐2b at 1.5 microg/kg/week with ribavirin (RBV) at 800 to 1400 mg/day
Trial: 20568303
Drug: peginterferon (PEG‐IFN)
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon (PEG‐IFN) alfa‐2b at 1.0 microg/kg/week with RBV at 800 to 1400 mg/day
Trial: 20568303
Drug: peginterferon (PEG‐IFN)
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon (PEG‐IFN) alfa‐2a at 180 microg/week with RBV at 1000 to 1200 mg/day
Trial: 3530158
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 1 mg daily
Trial: 10081520
Drug: Betaine 4
RxNorm normalized name: betaine 460 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 4 g daily
Trial: 7751897
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 100 mg/m2 intravenously on day 1 and Fluorouracil (FU) 5,000 mg/m2 over a 120-hour continuous infusion
Trial: 7751897
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) 400 mg/m2 over a 24-hour continuous infusion on day 1 and Fluorouracil (FU) with the same schedule
Trial: 31133629
Drug: Drug consumption
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug consumption for MSP
Trial: 28219458
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy - Cognitive Only (CPT)
Trial: 15565613
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 units subcutaneously weekly)
Trial: 12171679
Drug: SPF 15
RxNorm normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) applied 30 minutes before UVA irradiation.
Trial: 12171679
Drug: SPF 15
RxNorm normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPF 15 sunscreen containing 0.25% AGR (Eucerin Gel Cream Phase 2) with additional pretreatment using AGR-containing vehicle (Eucerin Gel Cream Phase 1) twice daily for 3 and 7 days.
Trial: 12171679
Drug: Pre-sun preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-sun preparation applied twice daily for 1 week before vacation and SPF 15 sunscreen used 30 minutes before sun exposure.
Trial: 12171679
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for acne aestivalis patients.
Trial: 7848005
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg daily for 10 days)
Trial: 7848005
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg every two days)
Trial: 7848005
Drug: Erythromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (30 g)
Trial: 3288075
Drug: Elevated intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated intranasal temperature (inhalation of saturated hot air at 42-44 degrees C)
Trial: 30426269
Drug: Contact points
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact points of the implant with femoral cortical bone
Trial: 27545871
Drug: 25% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% SLS formulation
Trial: 27545871
Drug: 12.5% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5% SLS formulation
Trial: 27545871
Drug: 3% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% SLS formulation
Trial: 27545871
Drug: Reference 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference 50% SLS formulation
Trial: 27545871
Drug: Alectinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib (600 mg)
Trial: 20836913
Drug: Annual medication
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual medication assessment as part of a Comprehensive Geriatric Assessment (CGA) by physicians (n = 361)
Trial: 18323492
Drug: Comparison therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison therapy
Trial: 10973767
Drug: Eptifibatide (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (180 microg/kg bolus followed by continuous infusion of 0.75 microg/kg/min for 72 hours)
Trial: 1501118
Drug: Diphenhydramine (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (100, 200 and 400 mg)
Trial: 1501118
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 and 4 mg)
Trial: 1501118
Drug: Methocarbamol (2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methocarbamol (2.25 and 9 g)
Trial: 30850411
Drug: Ulinastatin (intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (intravenously administered every 8 hours for a total of 600,000 U/day for five consecutive days)
Trial: 29174695
Drug: Inactivated oral
RxNorm normalized name: typhoid vaccine, inactivated oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated oral cholera vaccine (OCV)
Trial: 25076161
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice daily for 2 days before PET/CT scan
Trial: 16773037
Drug: Sustained-release fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release fampridine 25 mg b.i.d. (Group I)
Trial: 16773037
Drug: Sustained-release fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release fampridine 40 mg b.i.d. (Group II)
Trial: 12236050
Drug: Vaginal capsule
RxNorm normalized name: VAGINAL CAPSULE, HARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal capsule containing 200 mg progesterone
Trial: 12236050
Drug: Vaginal gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel containing 90 mg progesterone
Trial: 9822445
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load during intermediate NaCl diet
Trial: 9822445
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load after each diet
Trial: 2912427
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug therapy with lovastatin and colestipol
Trial: 1098542
Drug: Classical cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical cholera vaccine with yellow fever vaccine
Trial: 1098542
Drug: Purified fraction
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified fraction vaccine with yellow fever vaccine
Trial: 1098542
Drug: Classical cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical cholera vaccine
Trial: 1098542
Drug: Purified fraction
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified fraction vaccine
Trial: 28327122
Drug: Midodrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (20 mg) three times a day
Trial: 27885221
Drug: Trial Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial Gel B
Trial: 22995879
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive strategy with contemporary antithrombin regimens (bivalirudin or heparin plus glycoprotein IIb/IIIa inhibitor)
Trial: 18093307
Drug: Sudarshan Kriya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sudarshan Kriya and related practices (SK&P) - practiced daily for six weeks
Trial: 7982184
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release metoclopramide (CRM) 40 mg every 12 hours for 3 days
Trial: 7982184
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release metoclopramide (IRM) 20 mg every 6 hours for 3 days
Trial: 25545629
Drug: rasagiline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline 2 mg/day
Trial: 23642947
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Lf/IgF daily for 90 days
Trial: 20605427
Drug: Pudding with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudding with 10 g oat bran DF
Trial: 20605427
Drug: Pudding with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudding with 10 g wheat bran DF
Trial: 20605427
Drug: Pudding with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudding with 5 g wheat bran DF + 5 g oat bran DF
Trial: 1572248
Drug: Captopril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (2.5 or 5.0 mg slow intravenous bolus followed by continuous infusion of 1.5‐2.0 mg/h for 48 hours)
Trial: 1572248
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same mode of administration as captopril)
Trial: 21982313
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy-defibrillator (CRT-D)
Trial: 18507661
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin plus 1 mg glucagon